• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Chemother . Diagnostic significance of secondary bacteremia in patients with COVID-19

tetano

Editor, Senior Moderator
J Infect Chemother

. 2023 Jan 19;S1341-321X(23)00014-4.
doi: 10.1016/j.jiac.2023.01.006. Online ahead of print.
Diagnostic significance of secondary bacteremia in patients with COVID-19


Kensuke Nakagawara 1 , Hirofumi Kamata 2 , Shotaro Chubachi 1 , Ho Namkoong 3 , Hiromu Tanaka 1 , Ho Lee 1 , Shiro Otake 1 , Takahiro Fukushima 1 , Tatsuya Kusumoto 1 , Atsuho Morita 1 , Shuhei Azekawa 1 , Mayuko Watase 1 , Takanori Asakura 4 , Katsunori Masaki 1 , Makoto Ishii 5 , Akifumi Endo 6 , Ryuji Koike 6 , Hiroyasu Ishikura 7 , Tohru Takata 8 , Yasushi Matsushita 9 , Norihiro Harada 10 , Hiroyuki Kokutou 11 , Takashi Yoshiyama 11 , Kensuke Kataoka 12 , Yoshikazu Mutoh 13 , Masayoshi Miyawaki 14 , Soichiro Ueda 14 , Hiroshi Ono 15 , Takuya Ono 16 , Tomohisa Shoko 16 , Hiroyuki Muranaka 17 , Kodai Kawamura 17 , Nobuaki Mori 18 , Takao Mochimaru 19 , Mototaka Fukui 20 , Yusuke Chihara 20 , Yoji Nagasaki 21 , Masaki Okamoto 21 , Masaru Amishima 22 , Toshio Odani 23 , Mayuko Tani 24 , Koichi Nishi 24 , Yuya Shirai 25 , Ryuya Edahiro 25 , Akira Ando 26 , Naozumi Hashimoto 26 , Shinji Ogura 27 , Yuichiro Kitagawa 27 , Toshiyuki Kita 27 , Takashi Kagaya 28 , Yasuhiro Kimura 29 , Naoki Miyazawa 29 , Tomoya Tsuchida 30 , Shigeki Fujitani 31 , Koji Murakami 32 , Hirohito Sano 32 , Yuki Sato 33 , Yoshinori Tanino 33 , Ryo Otsuki 34 , Shuko Mashimo 34 , Mizuki Kuramochi 35 , Yasuo Hosoda 35 , Yoshinori Hasegawa 36 , Tetsuya Ueda 36 , Yotaro Takaku 37 , Takashi Ishiguro 37 , Akiko Fujiwara 38 , Naota Kuwahara 38 , Hideya Kitamura 39 , Eri Hagiwara 39 , Yasushi Nakamori 40 , Fukuki Saito 40 , Yuta Kono 41 , Shinji Abe 41 , Tomoo Ishii 42 , Takehiko Ohba 43 , Yu Kusaka 43 , Hiroko Watanabe 44 , Makoto Masuda 45 , Hiroki Watanabe 45 , Yoshifumi Kimizuka 46 , Akihiko Kawana 46 , Yu Kasamatsu 47 , Satoru Hashimoto 48 , Yukinori Okada 49 , Tomomi Takano 50 , Kazuhiko Katayama 51 , Masumi Ai 52 , Atsushi Kumanogoh 25 , Toshiro Sato 53 , Katsushi Tokunaga 54 , Seiya Imoto 55 , Yuko Kitagawa 56 , Akinori Kimura 57 , Satoru Miyano 58 , Naoki Hasegawa 3 , Seishi Ogawa 59 , Takanori Kanai 60 , Koichi Fukunaga 1 ; Japan COVID-19 Task Force
Affiliations

PMID: 36682606 DOI: 10.1016/j.jiac.2023.01.006

Abstract

Objectives: We investigated the occurrence of non-respiratory bacterial and fungal secondary infections, causative organisms, impact on clinical outcomes, and association between the secondary pathogens and mortality in hospitalized patients with coronavirus disease 2019 (COVID-19).

Methods: This was a retrospective cohort study that included data from inpatients with COVID-19 from multiple centers participating in the Japan COVID-19 Taskforce (April 2020 to May 2021). We obtained demographic, epidemiological, and microbiological data throughout the course of hospitalization and analyzed the cases of COVID-19 complicated by non-respiratory bacterial infections.

Results: Of the 1914 patients included, non-respiratory bacterial infections with COVID-19 were diagnosed in 81 patients (4.2%). Of these, 59 (3.1%) were secondary infections. Bacteremia was the most frequent bacterial infection, occurring in 33 cases (55.9%), followed by urinary tract infections in 16 cases (27.1%). Staphylococcus epidermidis was the most common causative organism of bacteremia. Patients with COVID-19 with non-respiratory secondary bacterial infections had significantly higher mortality, and a multivariate logistic regression analysis demonstrated that those with bacteremia (aOdds Ratio = 15.3 [5.97-39.1]) were at higher risk of death. Multivariate logistic regression analysis showed that age, male sex, use of steroids to treat COVID-19, and intensive care unit admission increased the risk for nosocomial bacteremia.

Conclusions: Secondary bacteremia is an important complication that may lead to poor prognosis in cases with COVID-19. An appropriate medical management strategy must be established, especially for patients with concomitant predisposing factors.

Keywords: Bacteremia; Fungemia; Mortality; SARS-CoV-2 infection; Secondary infection.
 
Back
Top Bottom